Pharma Firms Rush to Develop Advanced Ovarian Cancer Treatments

The advanced ovarian cancer pipeline is accelerating rapidly as numerous pharma companies work to develop treatments for this aggressive form of cancer.

DelveInsight's report highlights 10+ active players, including OncoQuest, Allarity Therapeutics, and AstraZeneca, who are developing 12+ pipeline therapies. These drugs include Topotecan, Paclitaxel, Carboplatin, Bevacizumab, Erlotinib, AZD0530, Olaparib, and Stenoparib.

The report also notes that some of these companies have recently initiated phase 3 studies or announced the continuation of sub-studies to provide continued treatment access. For instance, Merck Sharp & Dohme LLC has initiated a phase 3 study to learn if people who receive sac-TMT maintenance treatment with or without bevacizumab live longer without the cancer getting worse than those who receive standard care.

The advanced ovarian cancer pipeline report provides comprehensive insights into these emerging therapies, including their stage of development, route of administration, and molecular type. The report also highlights collaborations between companies, such as the exclusive global rights for the development and commercialization of Stenoparib held by Allarity Therapeutics.